Markets:

Overview

News

Currencies

International

Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

30.34 +0.22 (+0.73%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

June 21, 2023

Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak...

Via Benzinga

Nasdaq Tumbles 1%; Patterson Companies Earnings Beat Views ↗

June 21, 2023

U.S. stocks traded mostly lower midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday.

Via Benzinga

Why uniQure Stock Is Crashing Today ↗

June 21, 2023

Investors are focusing on the negative parts of the biotech company's interim results.

Via The Motley Fool

Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy ↗

June 21, 2023

The company is working on a one-time treatment for Huntington's disease.

Via Investor's Business Daily

6 Analysts Have This to Say About uniQure ↗

May 11, 2023

Via Benzinga

Analyst Ratings for uniQure ↗

March 07, 2023

Via Benzinga

Dow Drops Over 100 Points; Winnebago Industries Posts Downbeat Sales ↗

June 21, 2023

U.S. stocks traded lower this morning, with Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.41% to 33,914.60 while the NASDAQ fell 0.31%...

Via Benzinga

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

June 21, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy

June 20, 2023

Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 16, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure's Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst ↗

May 15, 2023

uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare

Via Benzinga

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

May 15, 2023

From uniQure Inc.

Via GlobeNewswire

Recap: uniQure Q1 Earnings ↗

May 09, 2023

uniQure (NASDAQ:QURE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:05 AM. Here's what investors need to know about the announcement. Earnings uniQure missed estimated earnings by...

Via Benzinga

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 09, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 02, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2023

From uniQure Inc.

Via GlobeNewswire

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗

March 10, 2023

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...

Via Benzinga

uniQure to Participate in Multiple Upcoming Industry Conferences in March

March 02, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Stock Trying To Close In On Key Technical Measure ↗

February 28, 2023

uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.

Via Investor's Business Daily

uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

February 28, 2023

UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market...

Via Benzinga

uniQure Announces 2022 Financial Results and Highlights Recent Company Progress

February 27, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

February 23, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B

February 21, 2023

From uniQure Inc.

Via GlobeNewswire

UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline ↗

January 31, 2023

UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

Via Benzinga

uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1

January 31, 2023

From uniQure Inc.

Via GlobeNewswire

3 Growth Stocks That Could Rocket Higher in 2023 ↗

January 06, 2023

Upcoming binary events could push these stocks to new all-time highs.

Via The Motley Fool

Newly Approved Drugs In US Command Over $200,000 On An Average ↗

January 05, 2023

The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.

Via Benzinga

Have A Look At William Blair's Top Biotech Picks For 2023 ↗

December 25, 2022

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

Via Benzinga

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 20, 2022

From uniQure Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.